908 Devices Q4 EPS Estimate Decreased by Leerink Partnrs

908 Devices Inc. (NASDAQ:MASS) – Equities research analysts at Leerink Partnrs reduced their Q4 2025 earnings per share estimates for 908 Devices in a report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.25) per share for the quarter, down from their prior estimate of ($0.24). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for 908 Devices’ current full-year earnings is ($1.99) per share. Leerink Partnrs also issued estimates for 908 Devices’ FY2026 earnings at ($1.10) EPS.

Several other analysts have also recently commented on MASS. Stephens reissued an “overweight” rating and issued a $6.00 price target on shares of 908 Devices in a report on Wednesday, January 15th. Leerink Partners reaffirmed a “market perform” rating and set a $4.00 price target (down from $12.00) on shares of 908 Devices in a research note on Wednesday, November 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 908 Devices in a research note on Saturday, January 18th. Finally, Stifel Nicolaus lowered their target price on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $5.33.

908 Devices Stock Down 2.5 %

Shares of 908 Devices stock opened at $2.74 on Thursday. The firm has a market cap of $95.37 million, a price-to-earnings ratio of -1.55 and a beta of 0.96. 908 Devices has a 52-week low of $1.81 and a 52-week high of $8.50. The company’s 50-day simple moving average is $2.36 and its 200-day simple moving average is $3.46.

Institutional Investors Weigh In On 908 Devices

A number of large investors have recently added to or reduced their stakes in the business. B. Riley Wealth Advisors Inc. acquired a new stake in shares of 908 Devices in the third quarter valued at approximately $45,000. Barclays PLC raised its stake in 908 Devices by 452.7% in the 3rd quarter. Barclays PLC now owns 46,214 shares of the company’s stock valued at $160,000 after purchasing an additional 37,853 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of 908 Devices by 1.2% during the third quarter. Geode Capital Management LLC now owns 567,788 shares of the company’s stock valued at $1,970,000 after buying an additional 6,634 shares during the period. State Street Corp increased its position in 908 Devices by 1.2% during the third quarter. State Street Corp now owns 479,044 shares of the company’s stock worth $1,662,000 after purchasing an additional 5,704 shares during the last quarter. Finally, Needham Investment Management LLC raised its position in 908 Devices by 100.0% in the third quarter. Needham Investment Management LLC now owns 100,000 shares of the company’s stock valued at $347,000 after purchasing an additional 50,000 shares during the period. 88.06% of the stock is owned by institutional investors and hedge funds.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.